STAT3 as a prognostic marker in human gastric cancer

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 4, 2009, Pages 505-507

  Jackson, Cameron B ^a   Giraud, Andrew S ^a  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE; MOLECULAR MARKER; STAT3 PROTEIN; STAT5 PROTEIN;

BIOLOGICAL ACTIVITY; CANCER CELL; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; EDITORIAL; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; STOMACH CANCER; WESTERN BLOTTING;

EID: 63849095654     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05822.x     Document Type: Editorial

References (20)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005 55 : 74 108.
2. Sakakura C, Hagiwara A, Nakanishi M et al. Differential gene expression profiles of gastric cancer cells established from primary tumour and malignant ascites. Br. J. Cancer 2002 87 : 1153 61.
3. Sipponen P. Gastric cancer: pathogenesis, risks, and prevention. J. Gastroenterol. 2002 37 (Suppl. 13 39 44.
4. Sipponen P, Marshall BJ. Gastritis and gastric cancer. Western countries. Gastroenterol. Clin. North Am. 2000 29 : 579 92, v vi.
5. Galizia G, Lieto E, Orditura M et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J. Surg. 2007 31 : 1458 68.
6. Sumiyoshi Y, Kakeji Y, Egashira A, Mizokami K, Orita H, Maehara Y. Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin. Cancer Res. 2006 12 : 5112 17.
7. Vidal O, Soriano-Izquierdo A, Pera M et al. Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J. Gastrointest. Surg. 2008 12 : 1005 14.
8. Sobin LH, Fleming ID. TNM Classification of Malignant Tumors, fifth edition. Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997 80 : 1803 4.
9. Bromberg JF, Wrzeszczynska MH, Devgan G et al. Stat3 as an oncogene. Cell 1999 98 : 295 303.
10. Jackson CB, Judd LM, Menheniott TR et al. Augmented gp130-mediated cytokine signalling accompanies human gastric cancer progression. J. Pathol. 2007 213 : 140 51.
11. Dauer DJ, Ferraro B, Song L et al. Stat3 regulates genes common to both wound healing and cancer. Oncogene 2005 24 : 3397 408.
12. Gritsko T, Williams A, Turkson J et al. Persistent activation of stat3 signaling induces survivin gene expression and confers resistance to apoptosis in human breast cancer cells. Clin. Cancer Res. 2006 12 : 11 19.
13. Kiuchi N, Nakajima K, Ichiba M et al. STAT3 is required for the gp130-mediated full activation of the c-myc gene. J. Exp. Med. 1999 189 : 63 73.
14. Dechow TN, Pedranzini L, Leitch A et al. Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C. Proc. Natl Acad. Sci. USA 2004 101 : 10602 7.
15. Ivanov VN, Bhoumik A, Krasilnikov M et al. Cooperation between STAT3 and c-jun suppresses Fas transcription. Mol. Cell 2001 7 : 517 28.
16. Kim D-Y, Cha S-T, Ahn D-H et al. STAT expression in gastric cancer indicates a poor prognosis. J. Gastroenterol. Hepatol. 2009 24 : 646 51.
17. Kanda N, Seno H, Konda Y et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. Oncogene 2004 23 : 4921 9.
18. Gong W, Wang L, Yao JC et al. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. Clin. Cancer Res. 2005 11 : 1386 93.
19. Sekikawa A, Fukui H, Fujii S et al. REG Ialpha protein mediates an anti-apoptotic effect of STAT3 signaling in gastric cancer cells. Carcinogenesis 2008 29 : 76 83.
20. Judd LM, Alderman BM, Howlett M et al. Gastric cancer development in mice lacking the SHP2 binding site on the IL-6 family co-receptor gp130. Gastroenterology 2004 126 : 196 207.